Velosef

Osteomyelitis, Peritonitis, Urinary Tract Infections + 5 more
Treatment
4 Active Studies for Velosef

What is Velosef

CefradineThe Generic name of this drug
Treatment SummaryA type of antibiotic that is a combination of synthetic and naturally occurring ingredients.
Velosefis the brand name
Velosef Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Velosef
Cefradine
1995
4

Effectiveness

How Velosef works in the bodyCefradine is an antibiotic that works by blocking the formation of bacterial cell walls. It attaches to proteins inside the cell wall and prevents it from fully forming. This causes the cell wall to break apart, leading to the death of the bacteria. It also might stop an enzyme from protecting the cell wall, making it even easier for the wall to break down.

When to interrupt dosage

The suggested dose of Velosef is contingent upon the diagnosed affliction, including Respiratory Tract Infections, Septic Arthritis and Sepsis Bacterial. The dosage amount oscillates based on the administration technique (e.g. Suspension or Capsule, gelatin coated - Oral) denoted in the table beneath.
Condition
Dosage
Administration
Urinary Tract Infections
500.0 mg, , 250.0 mg, 125.0 mg/mL, 250.0 mg/mL
Capsule, gelatin coated, , Oral, Capsule, gelatin coated - Oral, Suspension, Suspension - Oral
Osteomyelitis
500.0 mg, , 250.0 mg, 125.0 mg/mL, 250.0 mg/mL
Capsule, gelatin coated, , Oral, Capsule, gelatin coated - Oral, Suspension, Suspension - Oral
Peritonitis
500.0 mg, , 250.0 mg, 125.0 mg/mL, 250.0 mg/mL
Capsule, gelatin coated, , Oral, Capsule, gelatin coated - Oral, Suspension, Suspension - Oral
Respiratory Tract Infections
500.0 mg, , 250.0 mg, 125.0 mg/mL, 250.0 mg/mL
Capsule, gelatin coated, , Oral, Capsule, gelatin coated - Oral, Suspension, Suspension - Oral
Arthritis, Infectious
500.0 mg, , 250.0 mg, 125.0 mg/mL, 250.0 mg/mL
Capsule, gelatin coated, , Oral, Capsule, gelatin coated - Oral, Suspension, Suspension - Oral
Sepsis
500.0 mg, , 250.0 mg, 125.0 mg/mL, 250.0 mg/mL
Capsule, gelatin coated, , Oral, Capsule, gelatin coated - Oral, Suspension, Suspension - Oral
Sepsis
500.0 mg, , 250.0 mg, 125.0 mg/mL, 250.0 mg/mL
Capsule, gelatin coated, , Oral, Capsule, gelatin coated - Oral, Suspension, Suspension - Oral
Communicable Diseases
500.0 mg, , 250.0 mg, 125.0 mg/mL, 250.0 mg/mL
Capsule, gelatin coated, , Oral, Capsule, gelatin coated - Oral, Suspension, Suspension - Oral

Warnings

Velosef has two contraindications, hence it should not be taken when enduring any of the conditions delineated in the following table.Velosef Contraindications
Condition
Risk Level
Notes
Bacterial Meningitis
Do Not Combine
known hypersensitivity to the drug or any of the ingredients
Do Not Combine
There are 20 known major drug interactions with Velosef.
Common Velosef Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be increased when combined with Cefradine.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be increased when combined with Cefradine.
Alectinib
Major
The metabolism of Alectinib can be increased when combined with Cefradine.
Alpelisib
Major
The metabolism of Alpelisib can be increased when combined with Cefradine.
Aminophylline
Major
The metabolism of Aminophylline can be increased when combined with Cefradine.
image of a doctor in a lab doing drug, clinical research

Velosef Novel Uses: Which Conditions Have a Clinical Trial Featuring Velosef?

Currently, 15 active trials are being conducted to assess the potential of Velosef to combat Sepsis, Septic Arthritis and Peritonitis.
Condition
Clinical Trials
Trial Phases
Communicable Diseases
0 Actively Recruiting
Arthritis, Infectious
0 Actively Recruiting
Osteomyelitis
4 Actively Recruiting
Phase 4, Phase 2, Not Applicable
Respiratory Tract Infections
0 Actively Recruiting
Sepsis
0 Actively Recruiting
Sepsis
1 Actively Recruiting
Not Applicable
Peritonitis
0 Actively Recruiting
Urinary Tract Infections
0 Actively Recruiting

Velosef Reviews: What are patients saying about Velosef?

3.7Patient Review
3/30/2010
Velosef for Acute Infection of the Nose, Throat or Sinus
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about velosef

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Velosef tablet used for?

"Velosef is an antibiotic used to treat bacterial infections. It is a cephalosporin type of antibiotic that belongs to the beta-lactam group of antibiotics and works by stopping the production of the bacterial walls."

Answered by AI

Is Velosef an antibiotic?

"Velosef is a semi-synthetic cephalosporin antibiotic. It comes in the form of capsules containing 250 mg and 500 mg cephradine, and a suspension containing 125 mg and 250 mg per 5 mL dose."

Answered by AI

What is Cefradine used to treat?

"Cefradine 500mg caps can help treat bacterial infections of the respiratory and urinary tracts, as well as the skin and soft tissues. This includes infections such as sinusitis, pharyngitis, tonsillitis, laryngo-tracheo bronchitis and otitis media."

Answered by AI

What are the side effects of Velosef?

"Stomach-related side effects like nausea, vomiting, and diarrhea are some of the most commonly reported problems with cephradine. A few people taking the drug have also developed a serious condition called pseudomembranous colitis."

Answered by AI

Clinical Trials for Velosef

Image of Ronald Reagan UCLA Medical Center in Los Angeles, United States.

Next Day Clinic for Patient Care

18+
All Sexes
Los Angeles, CA
The Next Day Clinic (NDC) is a quality improvement initiative that will be launched and operated by UCLA Health starting July 22, 2024. Its goals are to improve patient care and safety and to maximize cost effectiveness. The way it does this is by identifying patients in the ED who would normally be admitted for low-acuity conditions, and diverting them to a high-acuity clinic the following day called the NDC. This will help decompress the ED and the hospital, and allow for overall higher quality care. The Health System has partnered with UCLA's Healthcare Value Analytics and Solutions \[UVAS\] group which specializes in these types of program evaluations. The analysis conducted by the study team will be used to directly inform NDC operations, scaling, and future plans.
Recruiting
Has No Placebo
Ronald Reagan UCLA Medical Center
Image of Boston Medical Center in Boston, United States.

Recovery Management Checkups for Opioid Use Disorder

18 - 65
All Sexes
Boston, MA
This project is a pilot study of an adapted intervention of an existing Opioid Use Disorder (OUD) treatment retention intervention called Recovery Management Checkups (RMC). This intervention has been adapted to better fit the experiences and unique issues of those that have been hospitalized with serious injection related infections (SIRI) based on the findings from a prior qualitative study from the principal investigator. This project plans to test the adapted intervention within a smaller group of participants to assess feasibility, acceptability, and calculate early findings of intervention efficacy. Hospitalizations for SIRIs are a unique entry point for patients to start their recovery journey with medications for OUD (MOUD), but many people do not remain on long-term treatment, despite evidence that indicates MOUDs reduce death and re-hospitalization after SIRIs. The study objectives are to: * Assess the implementation feasibility of the adapted RMC model for patients with SIRI and OUD. * Establish preliminary estimates of intervention efficacy. * Make further adaptions to the intervention that will reduce both known and unknown barriers to care and increase effectiveness in future larger scale trials. Findings from this pilot study will result in further intervention refinement to better fit the target population, and serve as the basis for a larger randomized control trial that will have aims focused on more in-depth analysis of the efficacy of this program
Recruiting
Has No Placebo
Boston Medical CenterSimeon Kimmel, MD
Image of Phoenix VA Health Care System, Phoenix, AZ in Phoenix, United States.

Rifampin for Osteomyelitis in Diabetics

18 - 89
All Sexes
Phoenix, AZ
The purpose of this research study is to determine if rifampin, an antibiotic (a medicine that treats infections), is effective in treating osteomyelitis (infection of the bone) of the foot in diabetic patients. Despite use of powerful antibiotics prescribed over a long period of time, many diabetic patients remain at a high risk for needing an amputation of part of the foot or lower leg because the osteomyelitis is not cured. Some small research studies have shown that addition of rifampin to other antibiotics is effective in treating osteomyelitis in both diabetics and non-diabetics. However, because few diabetics with osteomyelitis have been studied, there is no definite proof that it is better than the usual treatments for diabetic patients. If this study finds that adding rifampin to the usual antibiotics prescribed for osteomyelitis reduces the risk for amputations, doctors will be able to more effectively treat many Veteran patients with this serious infection. Improving treatment outcomes is an important healthcare goal of the VA.
Phase 4
Waitlist Available
Phoenix VA Health Care System, Phoenix, AZ (+32 Sites)Mary T Bessesen, MD
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security